The Hepatitis C Virus (HCV)–Trimera Mouse: A Model for Evaluation of Agents against HCV | Zendy

Ehud Ilan | Zendy; Joseph Arazi | Zendy; Ofer Nussbaum | Zendy; Arie Zauberman | Zendy; Rachel Eren | Zendy; Ido Lubin | Zendy; Lewis F. Neville | Zendy; Ofer BenMoshe | Zendy; Alberto Kischitzky | Zendy; Amir Litchi | Zendy; Ido Margalit | Zendy; Judith Gopher | Zendy; Samir Mounir | Zendy; Weizhong Cai | Zendy; Nili Daudi | Zendy; Ahamed Eid | Zendy; Oded Jurim | Zendy; Abraham Czerniak | Zendy; Eithan Galun | Zendy; Shlomo Dagan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Hepatitis C Virus (HCV)–Trimera Mouse: A Model for Evaluation of Agents against HCV

Author(s) -

Ehud Ilan,

Joseph Arazi,

Ofer Nussbaum,

Arie Zauberman,

Rachel Eren,

Ido Lubin,

Lewis F. Neville,

Ofer BenMoshe,

Alberto Kischitzky,

Amir Litchi,

Ido Margalit,

Judith Gopher,

Samir Mounir,

Weizhong Cai,

Nili Daudi,

Ahamed Eid,

Oded Jurim,

Abraham Czerniak,

Eithan Galun,

Shlomo Dagan

Publication year - 2002

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/338266

Subject(s) - hepatitis c virus , virology , viremia , flaviviridae , hepacivirus , virus , biology , hepatitis c , monoclonal antibody , liver transplantation , antibody , immunology , transplantation , medicine , surgery

The lack of small-animal models that are suitable for evaluation of agents used to treat infection with hepatitis C virus (HCV) severely hinders the assessment of potential new therapies for the disease. This study created such a model, termed the "HCV-Trimera" model. The HCV-Trimera model was developed by using lethally irradiated mice, reconstituted with SCID mouse bone marrow cells, in which human liver fragments infected ex vivo with HCV had been transplanted. Viremia (positive-strand HCV RNA levels) in HCV-Trimera mice peaked at approximately day 18 after liver transplantation, and an infection rate of 85% was reached. Viral replication in liver grafts was evidenced by the presence of specific negative-strand HCV RNA. The usefulness of this model for evaluation of anti-HCV agents was demonstrated by the ability of a small molecule (an HCV internal ribosomal entry site inhibitor) and an anti-HCV human monoclonal antibody (HCV AB(XTL)68) to reduce virus loads in HCV-Trimera mice in a dose-dependent manner.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research